|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
New York City,NY,US
|
|
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases.
Anavex is currently in a Phase 2a trial for Alzheimer's disease (AD) with lead therapeutic, ANAVEX 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the Sigma-1 Receptor. PART A topline data of our ongoing Phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. ANAVEX 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: Rett syndrome, as well is in epilepsy and multiple sclerosis (MS). In 2015, the Company was awarded a research by the Michael J. Fox Foundation (MJFF) to study ANAVEX 2-73 for the treatment of Parkinson’s disease.
Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.
|
Anavex Life Sciences Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Anavex Life Sciences email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Anavex Life Sciences customer service number in your country click here to find.
Christopher Missling is the CEO of Anavex Life Sciences. To contact Christopher Missling email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.